Co-Diagnostics holder updates stake to 0% ownership
Rhea-AI Filing Summary
Co-Diagnostics, Inc. received an amended Schedule 13G/A from Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, and Waqas Khatri reporting that they now beneficially own 0 shares of the company’s common stock, or 0% of the class.
The percentages are based on 60,892,582 shares of common stock outstanding as of November 11, 2025, as stated in Co-Diagnostics’ Form 10-Q. The filers state that any securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Positive
- None.
Negative
- None.
Insights
Key institutional holder updates its Co-Diagnostics position to 0% ownership.
Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, and Waqas Khatri report beneficial ownership of 0 shares, equal to 0% of Co-Diagnostics’ common stock. This reflects their position as of December 31, 2025.
The ownership percentages use 60,892,582 shares outstanding as of November 11, 2025, taken from Co-Diagnostics’ Form 10-Q. The filers certify that any securities were acquired and are held in the ordinary course of business and not to change or influence control of the issuer.
For investors, this document mainly serves as a regulatory update on institutional holdings. Future company filings may provide additional context on changes in the broader shareholder base and any shifts among other significant holders over later reporting dates.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the latest Schedule 13G/A report for CODX?
Who are the reporting persons in this Co-Diagnostics (CODX) Schedule 13G/A?
What percentage of Co-Diagnostics (CODX) does Ayrton Capital LLC currently report owning?
What does the filing say about intent to influence control of Co-Diagnostics (CODX)?
As of what date are the Co-Diagnostics (CODX) holdings reported in this Schedule 13G/A?
AI-generated analysis. How Rhea-AI works. Not financial advice.